|
1
|
Singer C, Stancu P, Coşoveanu S and Botu
A: Non-alcoholic fatty liver disease in children. Curr Health Sci
J. 40:170–176. 2014.PubMed/NCBI
|
|
2
|
Masarone M, Federico A, Abenavoli L,
Loguercio C and Persico M: Non alcoholic Fatty liver: Epidemiology
and natural history. Rev Recent Clin Trials. 9:126–133.
2014.PubMed/NCBI
|
|
3
|
Wang FS, Fan JG, Zhang Z, Gao B and Wang
HY: The global burden of liver disease: The major impact of China.
Hepatology. 60:2099–2108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mehta K, Van Thiel DH, Shah N and Mobarhan
S: Nonalcoholic fatty liver disease: Pathogenesis and the role of
antioxidants. Nutr Rev. 60:289–293. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guo J, Ren W, Li A, Ding Y, Guo W, Su D,
Hu C, Xu K, Chen H, Xu X, et al: Fat mass and obesity-associated
gene enhances oxidative stress and lipogenesis in nonalcoholic
fatty liver disease. Dig Dis Sci. 58:1004–1009. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Surapaneni KM and Jainu M: Comparative
effect of pioglitazone, quercetin and hydroxy citric acid on the
status of lipid peroxidation and antioxidants in experimental
non-alcoholic steatohepatitis. J Physiol Pharmacol. 65:67–74.
2014.PubMed/NCBI
|
|
7
|
Doehner W and Landmesser U: Xanthine
oxidase and uric acid in cardiovascular disease: Clinical impact
and therapeutic options. Semin Nephrol. 31:433–440. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sumida Y, Niki E, Naito Y and Yoshikawa T:
Involvement of free radicals and oxidative stress in NAFLD/NASH.
Free Radic Res. 47:869–880. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mackness M and Mackness B: Targeting
paraoxonase-1 in atherosclerosis. Expert Opin Ther Targets.
17:829–837. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang M, Lang X, Cui S, Zou L, Cao J, Wang
S and Wu X: Quantitative assessment of the influence of paraoxonase
1 activity and coronary heart disease risk. DNA Cell Biol.
31:975–982. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Manning PJ, Jong SA, Ryalls AR and
Sutherland WH: Paraoxonase 1 activity in chylomicrons and VLDL: The
effect of type 2 diabetes and meals rich in saturated fat and oleic
acid. Lipids. 47:259–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ferre N, Marsillach J, Camps J, Mackness
B, Mackness M, Riu F, Coll B, Tous M and Joven J: Paraoxonase-1 is
associated with oxidative stress, fibrosis and FAS expression in
chronic liver diseases. J Hepatol. 45:51–59. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marsillach J, Camps J, Ferré N, Beltran R,
Rull A, Mackness B, Mackness M and Joven J: Paraoxonase-1 is
related to inflammation, fibrosis and PPAR delta in experimental
liver disease. BMC Gastroenterol. 9:32009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Samy W and Hassanian MA: Paraoxonase-1
activity, malondialdehyde and glutathione peroxidase in
non-alcoholic fatty liver disease and the effect of atorvastatin.
Arab J Gastroenterol. 12:80–85. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Karsen H, Binici I, Sunnetcioglu M, Baran
AI, Ceylan MR, Selek S and Celik H: Association of paraoxonase
activity and atherosclerosis in patients with chronic hepatitis B.
Afr Health Sci. 12:114–118. 2012.PubMed/NCBI
|
|
16
|
Mingyue Z, Bing W, Qilong D, Ruining Y and
Hong Q: Study on the relationship between xanthine oxidase
paraoxonase-1 and occurrence and development of nonalcoholic fatty
liver disease. Chinese Hepatology. 19:323–328. 2014.
|
|
17
|
Tuyama AC and Chang CY: Non-alcoholic
fatty liver disease. J Diabetes. 4:266–280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Day CP and James OF: Steatohepatitis: A
tale of two ‘hits’? Gastroenterology. 114:842–845. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hijona E, Hijona L, Arenas JI and Bujanda
L: Inflammatory mediators of hepatic steatosis. Mediators Inflamm.
2010:8374192010.PubMed/NCBI
|
|
20
|
Stiuso P, Scognamiglio I, Murolo M,
Ferranti P, De Simone C, Rizzo MR, Tuccillo C, Caraglia M,
Loguercio C and Federico A: Serum oxidative stress markers and
lipidomic profile to detect NASH patients responsive to an
antioxidant treatment: A pilot study. Oxid Med Cell Longev.
2014:1692162014.PubMed/NCBI
|
|
21
|
Koruk M, Taysi S, Savas MC, Yilmaz O,
Akcay F and Karakok M: Oxidative stress and enzymatic antioxidant
status in patients with nonalcoholic steatohepatitis. Ann Clin Lab
Sci. 34:57–62. 2004.PubMed/NCBI
|
|
22
|
Parks DA and Granger DN: Xanthine oxidase:
Biochemistry, distribution and physiology. Acta Physiol Scand
Suppl. 548:87–99. 1986.PubMed/NCBI
|
|
23
|
Sarnesto A, Linder N and Raivio KO: Organ
distribution and molecular forms of human xanthine
dehydrogenase/xanthine oxidase protein. Lab Invest. 74:48–56.
1996.PubMed/NCBI
|
|
24
|
Morita M, Ishida N, Uchiyama K, Yamaguchi
K, Itoh Y, Shichiri M, Yoshida Y, Hagihara Y, Naito Y, Yoshikawa T
and Niki E: Fatty liver induced by free radicals and lipid
peroxidation. Free Radic Res. 46:758–765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rodrigo L, Hernández AF, López-Caballero
JJ, Gil F and Pla A: Immunohistochemical evidence for the
expression and induction of paraoxonase in rat liver, kidney, lung
and brain tissue. Implications for its physiological role. Chem
Biol Interact. 137:123–137. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karlsson H, Kontush A and James RW:
Functionality of HDL: Antioxidation and detoxifying effects. Handb
Exp Pharmacol. 224:207–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mackness MI, Arrol S and Durrington PN:
Paraoxonase prevents accumulation of lipoperoxides in low-density
lipoprotein. FEBS Lett. 286:152–154. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Marsillach J, Camps J, Beltran-Debón R,
Rull A, Aragones G, Maestre-Martínez C, Sabench F, Hernández M,
Castillo DD, Joven J, et al: Immunohistochemical analysis of
paraoxonases-1 and 3 in human atheromatous plaques. Eur J Clin
Invest. 41:308–314. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gür M, Çaylı M, Uçar H, Elbasan Z, Şahin
DY, Gözükara MY, Selek Ş, Koyunsever NY, Şeker T, Türkoğlu C, et
al: Paraoxonase (PON1) activity in patients with subclinical
thoracic aortic atherosclerosis. Int J Cardiovasc Imaging.
30:889–895. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fu AL and Wu SP: Single intravenous
injection of plasmid DNA encoding human paraoxonase-1 inhibits
hyperlipidemia in rats. Biochem Biophys Res Commun. 397:257–262.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rosenblat M, Vaya J, Shih D and Aviram M:
Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol
efflux via the ABCA1 transporter in association with increased HDL
binding to the cells: A possible role for lysophosphatidylcholine.
Atherosclerosis. 179:69–77. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gorąca A, Huk-Kolega H, Piechota A,
Kleniewska P, Ciejka E and Skibska B: Lipoic acid-biological
activity and therapeutic potential. Pharmacol Rep. 63:849–858.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rahimifard M, Navaei-Nigjeh M, Baeeri M,
Maqbool F and Abdollahi M: Multiple protective mechanisms of
alpha-lipoic acid in oxidation, apoptosis and inflammation against
hydrogen peroxide induced toxicity in human lymphocytes. Mol Cell
Biochem. 403:179–186. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Park S, Karunakaran U, Jeoung NH, Jeon JH
and Lee IK: Physiological effect and therapeutic application of
alpha lipoic acid. Curr Med Chem. 21:3636–3645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Carrier B, Wen S, Zigouras S, Browne RW,
Li Z, Patel MS, Williamson DL and Rideout TC: Alpha-lipoic acid
reduces LDL-particle number and PCSK9 concentrations in high-fat
fed obese Zucker rats. PLoS One. 9:e908632014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huerta AE, Navas-Carretero S,
Prieto-Hontoria PL, Martínez JA and Moreno-Aliaga MJ: Effects of
α-lipoic acid and eicosapentaenoic acid in overweight and obese
women during weight loss. Obesity (Silver Spring). 23:313–321.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leuschner UF, Lindenthal B, Herrmann G,
Arnold JC, Rössle M, Cordes HJ, Zeuzem S, Hein J and Berg T: NASH
Study Group: High-dose ursodeoxycholic acid therapy for
nonalcoholic steatohepatitis: A double-blind, randomized,
placebo-controlled trial. Hepatology. 52:472–479. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Perra A, Pibiri M, Sulas P, Simbula G,
Ledda-Columbano GM and Columbano A: Alpha-lipoic acid promotes the
growth of rat hepatic pre-neoplastic lesions in the
choline-deficient model. Carcinogenesis. 29:161–168.
2008.PubMed/NCBI
|
